Inmune Bio’s Promising INKmune Therapy and Strong Financials Merit a Buy Rating

Maxim Group analyst Jason McCarthy has maintained their bullish stance on INMB stock, giving a Buy rating yesterday.

Jason McCarthy has given his Buy rating due to a combination of factors, including the promising progress of Inmune Bio’s INKmune therapy in clinical trials and the company’s solid financial positioning. In the clinical development of INKmune, a novel NK cell-targeted therapy for metastatic castration-resistant prostate cancer (mCRPC), the first cohort has completed without significant adverse events. This advancement to the second cohort, along with the therapy’s unique mechanism that stimulates the body’s own NK cells, underpins its potential effectiveness and safety in treating cancer.

Furthermore, the company’s financial health has been strengthened by recent equity financings, which have extended its cash runway into the second half of 2025. This positions Inmune Bio well to continue its trials for both mCRPC and Alzheimer’s disease without immediate financial constraints. The potential for the warrants issued during the financing to bring in additional funds if exercised further bolsters this outlook, with expectations that the cash on hand could last into 2026. These strategic and financial developments contribute to the analyst’s optimistic view of the stock’s future performance.

McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Inmune Bio, and Atossa Therapeutics. According to TipRanks, McCarthy has an average return of -18.5% and a 28.02% success rate on recommended stocks.

In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $21.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Inmune Bio (INMB) Company Description:

Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer. Its products include INKMUNE and INB03. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.